683 Capital Management’s Cardlytics CDLX Stock Holding History

683 Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$898K	Buy	200,000 +55,000	+38%	+$411K	0.04%	123
2026 Q1	$1.52M	Buy	145,000 +4,990	+4%	+$48.7K	0.08%	124
2025 Q4	$1.61M	Buy	140,010 +22,510	+19%	+$348K	0.07%	114
2025 Q3	$2.86M	Sell	117,500 -47,500	-29%	-$791K	0.15%	98
2025 Q2	$2.71M	Buy	165,000 +10,000	+6%	+$173K	0.18%	96
2025 Q1	$2.82M	Buy	155,000 +24,000	+18%	+$686K	0.19%	97
2024 Q4	$4.86M	Sell	131,000 -91,510	-41%	-$3.5M	0.3%	67
2024 Q3	$7.12M	Buy	222,510 +12,510	+6%	+$694K	0.54%	49
2024 Q2	$17.2M	Buy	210,000 +10,260	+5%	+$1.11M	1.3%	21
2024 Q1	$28.9M	Buy	199,740 +46,240	+30%	+$3.9M	2.12%	14
2023 Q4	$14.1M	Sell	153,500 -22,507	-13%	-$2.29M	1.16%	33
2023 Q3	$29M	Sell	176,007 -28,993	-14%	-$3.77M	2.26%	12
2023 Q2	$13M	Buy	205,000 +22,500	+12%	+$1.36M	0.93%	31
2023 Q1	$6.2M	Buy	182,500 +7,500	+4%	+$392K	0.46%	63
2022 Q4	$10.1M	Sell	175,000 -15,000	-8%	-$927K	0.86%	36
2022 Q3	$17.9M	Buy	190,000 +21,526	+13%	+$3.06M	1.38%	24
2022 Q2	$37.6M	Buy	168,474 +11,574	+7%	+$3.88M	2.65%	6
2022 Q1	$86.3M	Buy	156,900 +5,378	+4%	+$3.25M	4.62%	3
2021 Q4	$100M	Buy	151,522 +5,000	+3%	+$3.82M	3.68%	7
2021 Q3	$123M	Buy	146,522 +55,413	+61%	+$56.2M	4.8%	3
2021 Q2	$116M	Buy	91,109 +53,109	+140%	+$59.9M	4%	5
2021 Q1	$41.7M	Sell	38,000 -28,000	-42%	-$37M	2.21%	11
2020 Q4	$94.2M	Sell	66,000 -34,077	-34%	-$36.3M	4.46%	6
2020 Q3	$70.6M	Buy	100,077 +14,416	+17%	+$10.5M	5.17%	3
2020 Q2	$59.9M	Sell	85,661 -1,000	-1%	-$577K	4.8%	3
2020 Q1	$30.3M	Buy	86,661 +29,161	+51%	+$20.7M	3.55%	4
2019 Q4	$36.1M	Buy	57,500 +20,000	+53%	+$9.78M	4.13%	3
2019 Q3	$12.6M	Buy	37,500 +25,711	+218%	+$8.24M	1.4%	23
2019 Q2	$3.06M	Buy	+11,789	New	+$2.36M	0.28%	69

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $122M AUM 11.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

683 Capital Management's CDLX Position: Q2 2026 in Review

683 Capital Management increased its Cardlytics (CDLX) stake by 38% in Q2 2026, buying an estimated $411K and bringing the position to 200,000 shares worth $898K. The position accounts for 0.04% of the portfolio, ranked #123.

683 Capital Management first reported a position in CDLX in Q2 2019 and has held it in 29 quarters since. The position peaked at $123M in Q3 2021. 42 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.

683 Capital Management held 200,000 shares of Cardlytics worth $898K as of Q2 2026.
683 Capital Management bought 55,000 Cardlytics shares in Q2 2026, an estimated $411K.
Cardlytics made up 0.04% of 683 Capital Management's portfolio in Q2 2026, its #123 holding.
683 Capital Management first reported a position in Cardlytics in Q2 2019 and has held it in 29 quarters since.
683 Capital Management's Cardlytics position peaked at $123M in Q3 2021.
42 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.